EN DE
Watch CSPC Innovation Pharmaceutical Co Ltd Class A for free: we tell you when fair value or trend changes.
Data-driven stock valuation

CSPC Innovation Pharmaceutical Co Ltd Class A (300765) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of CSPC Innovation Pharmaceutical Co Ltd Class A stock ¥19.06, price ¥34.78, that is 45.2% below the price, quality 37 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Consumer Defensive CN · ISIN CNE100003K04

CI CSPC Innovation Pharmaceutical Co Ltd Class A logo Thin data Nov 10, 2026

CSPC Innovation Pharmaceutical Co Ltd Class A

300765 · SHE
Very expensive, weak quality

Our calculation puts a fair price 45% below what the stock costs today.

Highly profitable · 23.5% net margin (TTM)
Low debt
Profit last quarter +53% vs. a year ago.
Moderate moat 54/100
Fair value ¥19.06 · Strongly overvalued
Quality 37/100
Weak Growth (revenue 3y −6.5 %/yr in CNY)
Negative free cash flow
Trails peers (5/13)
Thin data
Estimate⚠ Small free float
Watch CSPC Innovation Pharmaceutical Co Ltd Class A for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥63.00 ¥5.23 Fair Value ¥19.06 May 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range ¥5.23 – ¥63.00 · fair‑value band ¥14.30 – ¥23.83 · the ¥34.78 price screens above the ¥19.06 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow CSPC Innovation Pharmaceutical Co Ltd Class A in your weekly email

Every Wednesday you see whether CSPC Innovation Pharmaceutical Co Ltd Class A is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

CSPC Innovation Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of biopharmaceuticals, functional foods, and raw materials in China and internationally.

Show moreShow less

The company offers functional raw ingredients, including caffeine, acarbose, anhydrous glucose, theophylline, aminophylline, dyphylline, theobromine, pentoxifylline, and doxofylline; and health food products, such as Guoweikang Vitamin C tablets, Guoweikang B vitamin lozenges, etc.

It also provides technology transfer and technical consulting services of biotechnology. The company was founded in 2006 and is headquartered in Shijiazhuang, China. CSPC Innovation Pharmaceutical Co., Ltd. is a subsidiary of CSPC NBP Pharmaceutical Co., Ltd.

Stock analysis

CSPC Innovation Pharmaceutical Co Ltd Class A (300765) currently trades at ¥34.78, while our estimate is ¥19.06, 45% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: ¥14.30 (bear) to ¥23.83 (bull), the price of ¥34.78 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 37/100 (below-average quality), in the Consumer Defensive sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

CSPC Innovation Pharmaceutical Co Ltd Class A reported revenue of 2.1B CNY in FY2025 versus 1.8B CNY in FY2021, a compound +3.8%/yr. Reported net income was −241M CNY in FY2025.

Key figures

Market cap 48.4B CNY (≈ $7.3B) Mid · P/E ratio 47.6 · P/S ratio 11.1 · EPS (TTM) ¥0.7300 · Dividend yield 0.1% · Net margin 23.5% · Return on equity 26.1% · Return on assets (EBIT) 4.3% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 54 out of 100 (medium confidence).

What moves the price

The share trades about 33% below its 52-week high and 50% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Consumer Defensive peers we cover trades at 2% fair-value upside, at −45%, 300765 screens richer than that median.

Fair Value

Bear ¥14.30 Fair Value ¥19.06 Bull ¥23.83
Price ¥34.78 · Downside -45.2%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 37/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 8
How much profit the company makes from its sales and capital
Quality Growth 21
Are margins and returns getting better?
Cashflow 7
Do the profits arrive as real cash?
Financial strength 75
Debt, balance sheet and risk of trouble
Investment 48
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 42
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 27
Distance to the 52-week high, does not count
New shares 77
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+8.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−6.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.3%
Start year 2020 (pandemic). Over 10 years: +11.2% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
27.3% (2020) → −29.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

300765 screens overvalued: fair value 45% below the price. Compare with Nestlé S.A →

Compare CSPC Innovation Pharmaceutical Co Ltd Class A with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Packaged Foods · 660 stocks

Beats the industry median on 5/13 measures
Overall it trails its industry peers.
Valuation
Quality Score 37 · Bottom 25%
Fair Value upside −45.2% · Bottom 25%
Profitability
Return on equity (12 months) 26.1% · Top 25%
Return on assets −3.8% · Bottom 25%
Net margin (12 months) 23.5% · Top 25%
Operating margin (12 months) 65.8% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 345.9% · Top 25%
Dividend yield (12 months) 0.1% · Bottom 25%
Balance sheet
Debt / equity 0.01× · Lowest 25%

Valuation Multiplesvs Packaged Foods median · lower = cheaper

P/E (12 months) 47.6× · Priciest 25%
P/B 18.16× · Priciest 25%
P/S (12 months) 11.14× · Priciest 25%
EV/EBITDA 34.9× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 34
FUTURE (revenue growth)100 · sector 25
PAST (return on equity)100 · sector 30
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)1 · sector 55

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Packaged Foods stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Wilmar International Limited F34 2.95 SGD 4.93 SGD +67% vs 300765
Inner Mongolia Yili Industrial Group 600887 ¥31.14 ¥41.84 +34% vs 300765
The Kraft Heinz Company KHC $24.24 $29.20 +20% vs 300765
Foshan Haitian Flavouring and Food Company 603288 ¥35.46 ¥39.22 +11% vs 300765
General Mills, Inc GIS $34.60 $35.30 +2% vs 300765
Danone S.A BN €68.32 €50.65 −26% vs 300765
Nestlé S.A NESN CHF 86.41 CHF 59.51 −31% vs 300765
Kerry Group KRZ €97.10 €60.33 −38% vs 300765
Nestlé India Limited NESTLEIND ₹1,298 ₹724.74 −44% vs 300765
Yihai Kerry Arawana Holdings 300999 ¥25.92 ¥12.21 −53% vs 300765

Explore undervalued stocks

More undervalued Consumer Defensive stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

CSPC Innovation Pharmaceutical Co Ltd Class A: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "CSPC Innovation Pharmaceutical Co Ltd Class A Fair Value". https://www.fairvalue-calculator.com/stock/300765

Frequently asked questions

Is CSPC Innovation Pharmaceutical Co Ltd Class A (300765) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is ¥19.06 versus a price of ¥34.78, about 45% lower (overvalued).
What is the fair value of 300765?
Our estimate for CSPC Innovation Pharmaceutical Co Ltd Class A is ¥19.06 (as of Nov 10, 2026), built from audited fundamentals. The current price: ¥34.78.
What is the quality score of 300765?
CSPC Innovation Pharmaceutical Co Ltd Class A has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CSPC Innovation Pharmaceutical Co Ltd Class A (300765)?
Our calculated price target is the estimate of ¥19.06 (as of Nov 10, 2026). Cautious scenario ¥14.30, optimistic scenario ¥23.83. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the CSPC Innovation Pharmaceutical Co Ltd Class A stock forecast for 2026?
Our estimate puts fair value at ¥19.06, about 45% lower versus a price of ¥34.78 (overvalued). Cautious scenario ¥14.30, optimistic scenario ¥23.83. The calculation is refreshed regularly with new filings.
What is the revenue of CSPC Innovation Pharmaceutical Co Ltd Class A (300765)?
CSPC Innovation Pharmaceutical Co Ltd Class A reported trailing-twelve-month revenue of about 4.3B CNY (latest available figure, as of Nov 10, 2026).
Does CSPC Innovation Pharmaceutical Co Ltd Class A pay a dividend?
CSPC Innovation Pharmaceutical Co Ltd Class A currently shows a dividend yield of 0.07% relative to its recent price (as of Nov 10, 2026).
How much is the dividend of CSPC Innovation Pharmaceutical Co Ltd Class A (300765)?
CSPC Innovation Pharmaceutical Co Ltd Class A has a dividend yield of 0.1%.
What is the intrinsic value of CSPC Innovation Pharmaceutical Co Ltd Class A (300765)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CSPC Innovation Pharmaceutical Co Ltd Class A it is ¥19.06 per share (as of Nov 10, 2026), against a price of ¥34.78.
Is CSPC Innovation Pharmaceutical Co Ltd Class A stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 300765 trades above its calculated fair value: price ¥34.78, fair value ¥19.06, a gap of about −45% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 300765?
No. The price is what the market pays today (¥34.78); the fair value is what the company's own numbers justify (¥19.06). For CSPC Innovation Pharmaceutical Co Ltd Class A the two are ¥15.72 per share apart. That gap is exactly why we show both numbers side by side.
How much is CSPC Innovation Pharmaceutical Co Ltd Class A worth?
The market values CSPC Innovation Pharmaceutical Co Ltd Class A at about 48.4B CNY (market capitalisation, as of Nov 10, 2026). Per share that is ¥34.78; our models calculate a fair value of ¥19.06 per share.
What do the bullish and bearish scenarios say about 300765?
Our models span a range for CSPC Innovation Pharmaceutical Co Ltd Class A: cautious scenario ¥14.30, base ¥19.06, optimistic ¥23.83 per share (as of Nov 10, 2026, price ¥34.78). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 300765?
CSPC Innovation Pharmaceutical Co Ltd Class A trades at a price-to-earnings ratio of 47.6 (as of Nov 10, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥19.06 is built from several models across several years. Other multiples: P/B 18.2, P/S 11.1, EV/EBITDA 34.9.
How solid is the balance sheet of CSPC Innovation Pharmaceutical Co Ltd Class A (300765)?
Balance-sheet figures for CSPC Innovation Pharmaceutical Co Ltd Class A (as of Nov 10, 2026): return on equity 26.1%, debt of 0.01 per unit of equity. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is 300765 from its 52-week high?
CSPC Innovation Pharmaceutical Co Ltd Class A trades at ¥34.78, about 33% below its 52-week high of ¥51.78 and 50% above the low of ¥23.23 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of ¥19.06 is for.
Which stocks are comparable to CSPC Innovation Pharmaceutical Co Ltd Class A?
From the same area (Consumer Defensive) we also value Nestlé S.A, Danone S.A, Foshan Haitian Flavouring and Food Company, The Kraft Heinz Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CSPC Innovation Pharmaceutical Co Ltd Class A stock attractive at the current price?
The data as of Nov 10, 2026: price ¥34.78, calculated fair value ¥19.06 (−45%), Quality Score 37/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. CSPC Innovation Pharmaceutical Co Ltd Class A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of CSPC Innovation Pharmaceutical Co Ltd Class A (300765)?
The closing price on Nov 10, 2026 was ¥34.78. Our estimate is ¥19.06, about 45% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CSPC Innovation Pharmaceutical Co Ltd Class A right now?
The price sits above even our optimistic bull case (¥23.83). The favourable scenario is already priced in. Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of CSPC Innovation Pharmaceutical Co Ltd Class A

How large is the market capitalisation of CSPC Innovation Pharmaceutical Co Ltd Class A (300765)?
The market capitalisation of CSPC Innovation Pharmaceutical Co Ltd Class A is 48.4B CNY (≈ $7.3B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of CSPC Innovation Pharmaceutical Co Ltd Class A (300765)?
The price-to-sales ratio of CSPC Innovation Pharmaceutical Co Ltd Class A is 11.1 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of CSPC Innovation Pharmaceutical Co Ltd Class A (300765)?
Earnings per share at CSPC Innovation Pharmaceutical Co Ltd Class A are ¥0.7300 (price ÷ EPS = P/E 47.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of CSPC Innovation Pharmaceutical Co Ltd Class A (300765)?
The dividend yield of CSPC Innovation Pharmaceutical Co Ltd Class A is 0.1% (payout 3.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of CSPC Innovation Pharmaceutical Co Ltd Class A (300765)?
The net margin of CSPC Innovation Pharmaceutical Co Ltd Class A is 23.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of CSPC Innovation Pharmaceutical Co Ltd Class A (300765)?
The return on equity (ROE) of CSPC Innovation Pharmaceutical Co Ltd Class A is 26.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CSPC Innovation Pharmaceutical Co Ltd Class A (300765)?
On an EBIT basis the return on assets of CSPC Innovation Pharmaceutical Co Ltd Class A is 4.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CSPC Innovation Pharmaceutical Co Ltd Class A (300765)?
The operating margin of CSPC Innovation Pharmaceutical Co Ltd Class A is 65.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at CSPC Innovation Pharmaceutical Co Ltd Class A (300765)?
Revenue at CSPC Innovation Pharmaceutical Co Ltd Class A is growing +346% versus a year earlier (3y avg −6.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at CSPC Innovation Pharmaceutical Co Ltd Class A (300765)?
Earnings per share at CSPC Innovation Pharmaceutical Co Ltd Class A are growing +53.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does CSPC Innovation Pharmaceutical Co Ltd Class A (300765) generate?
The free cash flow of CSPC Innovation Pharmaceutical Co Ltd Class A is −764M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does CSPC Innovation Pharmaceutical Co Ltd Class A (300765) hold?
CSPC Innovation Pharmaceutical Co Ltd Class A holds more cash than debt, 767M CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch CSPC Innovation Pharmaceutical Co Ltd Class A in the live analysis

One click puts CSPC Innovation Pharmaceutical Co Ltd Class A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.